Pittsburgh compound-B (PiB), an amyloid-binding positron emission tomography (PET) tracer, is widely used for imaging amyloid-b in those with and at risk for Alzheimer disease. Here, we report on an otherwise normal 68-year-old female with abnormally high and very focal PiB retention. Coregistered T1weighted magnetic resonance imaging and dynamic 2-fluoro-2-deoxy-D-glucose (FDG) images confirmed that the focal PiB enhancement was in the superior sagittal and transverse sinuses, outside of the adjacent cortex. Flow through the venous vasculature was normal as assessed by dynamic FDG PET imaging. These features supported the conclusion that PiB retention was not simply due to a hemodynamic abnormality, but may have represented PiB binding to fibrillar deposits of a b-sheet protein (ie, amyloid), whose nature is currently unclear.
P ittsburgh compound-B (PiB) is a positron emission tomography (PET) tracer that binds amyloid-b deposits with high specificity, enabling PET imaging of amyloid aggregates in Alzheimer disease (AD) patients. 1, 2 PiB is a powerful tool for studying AD and has been used for a wide range of clinical and basic disease research. 3 Since the first human PiB scans in 2002, several thousands of patients have received PiB imaging at more than 50 centers around the world. PiB is currently used to monitor therapy in a number of clinical trials 4, 5 and may eventually see clinical use to help diagnose dementia. 2, [6] [7] [8] [9] Further, recent advances in F 18 -labeled amyloid imaging agents such as Amyvid, 10 Flutemetamol, 11 , and Florbetaben 12 have made amyloid imaging more accessible due to the longer half-life of F 18 , making the transport of these compounds to remote PET imaging sites possible. As amyloid imaging becomes more widespread, it is important to document and study amyloid imaging variants. Here, we describe an otherwise normal individual with unusual PiB retention in the venous sinuses.
METHODS

Imaging
PiB and 2-fluoro-2-deoxy-D-glucose (FDG) PET and structural magnetic resonance imaging (MRI) studies were performed as described previously in detail. 13, 14 MR images were acquired on a 1.5 T scanner using a spoiled gradient recall sequence and coregistered with PET images using automated methods. 15, 16 
Image Analysis
Region-of-interest-based analyses and PiB(-) case definitions were performed as described previously. 7, 13, 14, 17 Volumes of interest (VOIs) for the venous sinuses and internal carotids were determined using the initial "washin" frames (t = 0 to 2 min) on FDG scans. We defined the venous sinus VOIs using an oval (16.52 mm 2 ) drawn in 5 consecutive slices (2.46 mm per slice) centered at the confluence of the superior sagittal sinus and the transverse sinuses. Carotid VOIs were drawn bilaterally with an oval (24.26 cm 2 ) on 5 slices spanning the cavernous segment of the internal carotid. Subgenual anterior cingulate and precuneus VOIs were generated in a previous study. 13 Venous anatomy was assessed using the t = 45 seconds acquisition from the dynamic FDG scan, which approximates the venous phase. At this time point, FDG is primarily pooling in the venous circulation, allowing clear visualization of the venous anatomy. Raw FDG images were median filtered and thresholded to remove noise.
RESULTS
The patient, referred to hereafter as C49, was a 68year-old female with an unremarkable medical history. She was evaluated with the standard neurological, psychiatric, and neuropsychological examinations used at the University of Pittsburgh Alzheimer Disease Research Center (ADRC) as described previously. 7, 13, 18 All participants provided informed consent for both the ADRC clinical examination and the PET imaging protocol. This study was approved by the Human Use Subcommittee of the Radioactive Drug Research Committees and the Institutional Review Board of the University of Pittsburgh.
C49 was enrolled as a cognitively normal control. Five other cognitively normal controls with no PiB retention [ie, PiB negative (À ) controls] were used for comparison in the following analysis. C49 received identical assessments and imaging at a 12-month follow-up study.
Imaging MRI scans were normal as read by an experienced radiologist. On PiB PET scans, C49 exhibited enhancement in the venous sinuses, beginning in the superior sagittal sinus at the level of the superior parietal lobe, descending to the confluence of the sinuses, and continuing laterally along both transverse sinuses (Fig. 1 ). The straight sinus did not exhibit PiB enhancement. Localization to the venous sinuses was confirmed by T1-weighted MRI (Fig. 1 , top row) and by the venous phase of a dynamic FDG scan ( Fig. 2) . When overlaid on the MRI, the PiB signal at the superior sagittal sinus and the sinus confluence overlapped slightly with adjacent cortex, likely a result of the pointspread function of PET reconstruction (approximately 6 mm full width at half maximum). 15, 16, 19 PiB retention in all other brain regions was negligible. The 1-year follow-up PiB imaging study in C49 showed similar PiB retention in the venous sinuses (not shown).
We quantified these observations by comparing PiB standardized uptake values (SUVs) in C49 (n = 2, baseline scan and 1 y rescan) and PiB(À ) control scans (n = 5) for VOIs including the venous sinuses, internal carotids, subgenual anterior cingulate cortex, and precuneus cortex. The venous sinus PiB SUV was higher in C49 compared with the controls at late time-points (Fig. 3A) . When normalized to the carotid arteries, which approximate the vascular input function and control for dosage and hemodynamic differences between participants, the C49 sinus PiB SUV was 25% to 46% greater than the controls at late time points ( Fig. 3B ). Other brain regions that are often the first to show increased PiB retention in PiB(+) controls, such as the subgenual anterior cingulate and the precuneus cortex, did not retain PiB in C49 or PiB( À) controls (data not shown). In summary, C49 exhibited focal PiB retention in the venous sinuses, with otherwise normal PiB retention throughout the brain. We hypothesized that an apparent increase in venous sinus PiB retention in C49 could be an artifact of hemodynamic abnormalities in the sinus. In that case, the pharmacokinetics of other tracers should be similarly affected. We thus compared the PiB PET findings with those obtained during a 2-fluoro-2-deoxy-D-glucose study. FDG, a glucose analog, normally distributes quickly (<1 min) and accumulates only in metabolically active cells; the FDG signal in vascular structures, such as the carotids, normally decreases rapidly to baseline after the intravenous bolus.
Sinus FDG in C49 decreased quickly after intravenous administration compared with sinus PiB, which cleared relatively slowly (see Figs. 3A, C). C49 sinus FDG kinetics were similar to, if not slightly faster than, sinus FDG kinetics in PiB( À) controls (Figs. 3C, D) . In contrast, sinus PiB in C49 washed out more slowly than PiB( À ) controls and seemed to plateau at late times (eg, 60 to 90 min, Figs. 3A, B ).
DISCUSSION
We observed anomalous PiB retention in the venous sinuses of a cognitively normal individual. PiB distribution volume ratio was abnormally high in the superior sagittal and transverse sinuses, but was typical of other PiB( À) controls in other regions of the brain. When overlaid on the MR image, PiB enhancement was clearly associated with dural structures outside of the brain parenchyma (Fig. 1,  bottom row) .
In this case, sinus PiB enhancement did not seem to be the result of a hemodynamic abnormality, because another tracer, FDG, was not retained abnormally in the sinuses. In fact, the sinus FDG signal in our participants was lower than the PiB(À ) controls for later time-points, suggesting more complete vascular clearance (Fig. 3C ). It should be noted that sinus FDG was, in some patients, partially contaminated from surrounding cortical structures because of VOI placement and reconstruction constraints, and therefore increased at later timepoints(>10 min) (Figs. 3C, D) , PiB(À ) controls). These findings support the hypothesis that the abnormal PiB retention was caused by a b-sheet structured protein aggregate deposited in the walls of the venous sinuses. To our knowledge, there is no precedent for cerebral amyloid angiopathy in the venous sinuses, and this is the first venous sinus PiB enhancement seen at our institution after >300 subjects. It is unlikely that the PiB retention was the result of systemic amyloidosis, because our patient had no history of primary or secondary amyloidosis. Furthermore, to our knowledge, there is no record in the literature of systemic amyloidosis manifesting in the venous sinus. Finally, C49 had no history of B-cell lymphoma, a condition reported to be associated with the presence of amyloid in the dura. 20 Thus, if there is a PiBenhancing amyloid deposit in the venous sinuses of this case, its identity remains uncertain.
This case provides multiple warnings about PiB imaging and analysis. First, when PiB enhancement occurs at the extreme edges of the brain, a coregistered MRI can be helpful for corroborating cortical versus extracortical signal. We have recently observed a small number of patients with the clinical diagnosis of mild cognitive impairment or early AD who exhibit focal PiB enhancement in the occipital pole. In such cases, care should be taken to distinguish cortical amyloid from deposits in the sinus and might be better informed using overlaid PET-MRI composite images.
Second, in studying this case, we discovered that the image processing protocol used to generate parametric images from raw PET measurements sometimes obscured the PiB signal coming from areas outside of the brain boundaries. During our processing stream, the analyst draws a mask around the brain boundaries, as seen on the MRI, which is then used to suppress all PET signals outside of the brain in subsequent parametric images. In some cases, including the initial analysis of the 12-month rescan study of our patient, the mask excluded focal PiB enhancement in dural structures. Thus, we suspect that reassessment of imaging archives might uncover other cases of extracortical PiB retention. In summary, we have described a PiB imaging variant with anomalous PiB enhancement in the venous sinuses that is apparently not a result of a hemodynamic abnormality. Care must be taken with PiB, and presumably other amyloid-imaging tracers, so as to not misread sinus retention as parenchymal retention.
